儿童与青少年霍奇金淋巴瘤患者按年龄分层的生存分析:儿童肿瘤学组试验的回顾性汇总分析
该回顾性汇总分析纳入2002年9月23日至2012年1月19日期间在美国和加拿大三项儿童肿瘤学组(COG)3期试验中登记的1-21岁经典霍奇金淋巴瘤患者1907例,按年龄比较生存。中位随访7.4年后,≥15岁患者5年无事件生存率和总生存率均劣于<15岁患者,混合细胞型组织学中年龄差异更明显。
要点
- ≥15岁患者5年无事件生存率80% vs <15岁患者86%(HR 1.38,p=0.0038)。
- ≥15岁患者5年总生存率96% vs <15岁患者99%(HR 2.50,p=0.0012)。
- 混合细胞型中≥15岁患者多变量模型事件风险HR 3.72(p=0.0032)。
核心结论
- 在COG霍奇金淋巴瘤试验中接受治疗的青少年(≥15岁)较儿童(<15岁)无事件生存率更差且死亡风险增加。
- 作者指出需要前瞻性研究探讨肿瘤和宿主生物学,并在各年龄段测试新疗法。
研究设计与样本
- 回顾性汇总分析,纳入2002年9月23日至2012年1月19日期间在美国和加拿大三项COG 3期试验中登记的1-21岁经典霍奇金淋巴瘤患者。
- 三项试验按Ann Arbor分期、B症状和肿块定义风险组:AHOD0431(低危;NCT00302003)、AHOD0031(中危;NCT00025259)、AHOD0831(高危;NCT01026220)。
- 共2155例患者登记,1907例(88.4%)纳入分析;其中男性968例(50.8%),女性939例(49.2%),非西班牙裔白人1227例(64.3%)。
- 中位随访7.4年(IQR 4.3-10.2)。
- 采用Cox比例风险模型估计生存,校正疾病和治疗因素,分别在全人群及混合细胞型或非混合细胞型(结节硬化型和未另行指定型)疾病患者中分析。
主要发现
- ≥15岁患者未校正5年无事件生存率为80%(95%CI 78-83),<15岁患者为86%(95%CI 83-88);HR 1.38(95%CI 1.11-1.71),p=0.0038。
- ≥15岁患者未校正5年总生存率为96%(95%CI 95-97),<15岁患者为99%(95%CI 98-99);HR 2.50(95%CI 1.41-4.45),p=0.0012。
- 非混合细胞型组织学中,≥15岁患者较同组织学<15岁患者事件风险显著增加,HR 1.32(95%CI 1.03-1.68),p=0.027。
- 混合细胞型中,≥15岁患者未校正5年无事件生存率为77%(95%CI 65-86),<15岁患者为94%(95%CI 88-97);HR 2.93(95%CI 1.37-6.29),p=0.0039;多变量模型HR 3.72(95%CI 1.56-8.91),p=0.0032。
- 总体而言,≥15岁患者较<15岁患者死亡可能性更高,HR 3.08(95%CI 1.49-6.39),p=0.0025。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adolescents with Hodgkin lymphoma have worse disease outcomes than children. Whether these differences persist within clinical trials is unknown. We examined survival, by age, in patients receiving response-adapted therapy for Hodgkin lymphoma on Children's Oncology Group (COG) trials. METHODS: Patients (aged 1-21 years) diagnosed with classical Hodgkin lymphoma and enrolled between Sept 23, 2002, and Jan 19, 2012, on one of three phase 3 COG trials in the USA and Canada were eligible for inclusion. The three COG trials were defined by risk group according to Ann Arbor stage, B-symptoms, and bulk (AHOD0431 [low risk; NCT00302003], AHOD0031 [intermediate risk; NCT00025259], or AHOD0831 [high risk; NCT01026220]). The outcomes of this study were event-free survival (death, relapse, or subsequent neoplasm) and overall survival. Cox proportional hazards models estimated survival, adjusting for disease and treatment factors both overall and in patients with mixed cellularity or non-mixed cellularity (nodular sclerosing and not-otherwise-specified) disease. FINDINGS: Of 2155 patients enrolled on the three trials, 1907 (88·4%; 968 [50·8%] male and 939 [49·2%] female; 1227 [64·3%] non-Hispanic White) were included in this analysis. After a median follow-up of 7·4 years (IQR 4·3-10·2), older patients (aged ≥15 years) had worse unadjusted 5-year event-free survival (80% [95% CI 78-83]) than did younger patients (aged <15 years; 86% [83-88]; HR 1·38 [1·11-1·71]; p=0·0038). Older patients also had worse unadjusted 5-year overall survival than did younger patients (96% [95% CI 95-97] vs 99% [98-99]; HR 2·50 [1·41-4·45]; p=0·0012). In patients with non-mixed cellularity histology, older patients had a significantly increased risk of having an event than did younger patients with the same histology (HR 1·32 [1·03-1·68]; p=0·027). Older patients with mixed cellularity had significantly worse 5-year event-free survival than did younger patients in unadjusted (77% [95% CI 65-86] for older patients vs 94% [88-97] for younger patients; HR 2·93 [1·37-6·29]; p=0·0039) and multivariable models (HR 3·72 [1·56-8·91]; p=0·0032). Overall, older patients were more likely to die than younger patients (HR 3·08 [1·49-6·39]; p=0·0025). INTERPRETATION: Adolescents (≥15 years) treated on COG Hodgkin lymphoma trials had worse event-free survival and increased risk of death compared with children (<15 years). Our findings highlight the need for prospective studies to examine tumour and host biology, and to test novel therapies across the age spectrum. FUNDING: National Institutes of Health, St Baldrick's Foundation, and Lymphoma Research Foundation.
引用
- Kahn JM, Pei Q, Friedman DL, et al. Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials. Lancet Haematol. 2022. PMID: 34971582. doi:10.1016/S2352-3026(21)00349-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。